Skip to main content

Table 5 Number of quality assessment criteria addressed by individual studies

From: A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine

Journal articles
  Batty AJ, et al Giannouchos TV, et al Hansson-Hedblom A, et al Hollier-Hann G, et al Lipton RB, et al Mahon R, et al Ruggeri, et al. Sussman M, et al Vekov, et al
CHEERS 2022 (n = 28)
 Yes 25 23 23 23 22 25 23 25 12
 No 2 2 2 3 2 2 2 2 10
 Partial 1 3 3 2 4 1 3 1 6
 Unclear 0 0 0 0 0 0 0 0 0
 Not applicable 0 0 0 0 0 0 0 0 0
PHILIPS CRITERIA (n = 57)
 Yes 51 50 50 49 51 51 50 51 20
 No 3 4 4 6 4 3 3 3 16
 Partial 3 3 2 2 2 2 2 3 9
 Unclear 0 0 0 0 0 0 1 0 10
 Not applicable 0 0 1 0 0 1 1 0 2
Other reports
  CADTH (Botox) CADTH (Erenumab) ICER NICE (Erenumab) NICE (Fremanezumab) NICE (Galcenzenumab) Warwick Evidence (Botox)  
CHEERS 2022 (n = 27)
 Yes 27 26 25 27 27 27 24  
 No 1 1 1 1 1 1 1  
 Partial 0 1 2 0 0 0 3  
 Unclear 0 0 0 0 0 0 0  
 Not applicable 0 0 0 0 0 0 0  
PHILIPS CRITERIA (n = 57)
 Yes 50 49 52 53 54 55 55  
 No 3 2 1 2 1 0 0  
 Partial 4 6 4 1 1 1 2  
 Unclear 0 0 0 1 1 1 0  
 Not applicable 0 0 0 0 0 0 0